Millions more people accessing health products supported by MedAccess’ guarantees
26 June 2025 | News
More than 559 million people in over 115 countries have benefitted from health products supported by MedAccess’ guarantees since 2017, new data released today shows.
MedAccess’ 2024 Annual Review highlights progress in accelerating access to products that tackle life-threatening illnesses including HIV, tuberculosis and malaria as well as preparations to play an increasing role in tackling non-communicable diseases.
Key highlights from 2024 include:
- The rollout of G6PD testing and single use tafenoquine to tackle P. vivax malaria. MedAccess provided a volume guarantee to SD Biosensor to help stabilise the G6PD testing market. The World Health Organization recommends G6PD tests before prescribing treatment as people who are deficient in the G6PD enzyme can suffer severe anaemia from the treatment.
- Children in Cameroon became the first outside pilot countries to be protected with RTS,S – the world’s first malaria vaccine. Production of the vaccine was under threat in 2021 while the manufacturer awaited policy and funding approvals. MedAccess, Gavi and GSK entered into an innovative financing arrangement to ensure continued production of the RTS,S antigen. As a result, when the vaccine received positive policy and funding decisions, doses were available to be shipped following Gavi’s country approval process.
- Preparation for MedAccess’ first agreements on non-communicable diseases and malnutrition. The work done in 2024 enabled MedAccess to announce partnerships in 2025 to increase access to radiotherapy treatment for cancer and to vitamin A supplements for food fortification.
During 2024, MedAccess made key appointments at senior levels. Cyrus Ardalan, Alison Evans, Angela Gichaga and Anil Soni joined the Board while Asif Ali and Panayota Bird were appointed as Access Directors. These appointments add to MedAccess’ expertise and experience in global health and development, innovative finance and the pharmaceutical industry.
Preparations also got underway in 2024 for work on the next MedAccess strategy. The strategy will set out how MedAccess’ market shaping tools will address global health challenges in an era of reduced donor support and increased pressure on domestic resources.
